Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

Intravascular imaging improves survival in heart disease patients undergoing stent placement

Using intravascular imaging to guide stent implantation during percutaneous coronary intervention (PCI) in heart disease patients significantly improves survival and reduces adverse cardiovascular events compared to angiography-guided PCI alone, the most commonly used method.

22 Feb 2024

Extended P2Y12 inhibitor monotherapy reduces bleeding and ischemic events in ACS patients

Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischemic events in acute coronary syndrome (ACS) patients at high risk for both types of events.

29 Aug 2023

OCT-guided PCI does not reduce target vessel failure in complex patients, but improves safety

Optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) leads to a larger minimum stent area but does not reduce the two-year rate of target vessel failure compared with angiography-guided PCI, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

Dual-antiplatelet therapy should remain the standard strategy for PCI even in the drug-eluting stent era

Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not superior to dual-antiplatelet therapy (DAPT) for major bleeding but is non-inferior for cardiovascular events in patients with acute coronary syndrome (ACS) or high bleeding risk (HBR), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

28 Aug 2023

Bioresorbable vascular scaffolds may be just as effective as drug-eluting metal stents for treating heart disease patients

First-generation bioresorbable vascular scaffolds (BVS) may be just as effective as drug-eluting metallic stents, which are currently the standard treatment for heart disease patients undergoing percutaneous coronary intervention (PCI).

17 May 2023

Research investigates how drug-eluting stent affects arterial tissue permeability and blood flow

For patients with symptomatic coronary artery disease, the best course of action often involves implanting a drug-eluting stent into the artery where a plaque buildup is blocking blood flow to the heart.

2 Sep 2021

New exosome-coated stent repairs damaged tissue, heals vascular injury

Researchers from North Carolina State University have developed an exosome-coated stent with a "smart-release" trigger that could both prevent reopened blood vessels from narrowing and deliver regenerative stem cell-derived therapy to blood-starved, or ischemic, tissue.

6 Apr 2021

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

In a new publication from Cardiovascular Innovations and Applications, Nathan Burke, Tawanna Charlton, Hussam Hawamdeh, and Ki Park from the University of Florida College of Medicine, Gainesville.

20 Nov 2020

Short, one-month dual anti-platelet treatment is safe and effective after stent placement

A one-month treatment of dual anti-platelet therapy is safe and as effective as a longer duration of therapy at preventing cardiac events in patients one year after stent placement, according to late-breaking research presented today at the American Heart Association's Scientific Sessions 2020.

16 Nov 2020

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

The POPular TAVI trial has challenged current guideline recommendations on antiplatelet treatment after transcatheter aortic valve implantation (TAVI) in patients not taking oral anticoagulation. The findings are presented in a Hot Line session today at ESC Congress 2020.

31 Aug 2020

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus Brilinta in high-risk coronary patients.

From AstraZeneca 30 Mar 2020

Polymer drug-eluting and polymer-free drug-coated stents safe and effective for patients with high bleeding risk

The first randomized trial to compare a durable polymer drug-eluting stent to a polymer-free drug-coated stent in patients at high risk of bleeding and treated with one-month dual antiplatelet therapy (DAPT) found that both are clinically safe and effective.

27 Sep 2019

Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

New data from the randomized, placebo-controlled TWILIGHT trial found that compared to ticagrelor plus aspirin, ticagrelor monotherapy reduces bleeding events without increasing the risk of death, myocardial infarction, or stroke in high-risk patients who have undergone successful percutaneous coronary intervention and completed three months of dual antiplatelet therapy.

27 Sep 2019

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy did not increase myocardial infarction or stent thrombosis in high bleeding risk patients treated with a contemporary drug-eluting stent.

27 Sep 2019

High-risk heart patients may not require long-term aspirin use after stent placement

High-risk patients undergoing coronary stent procedures may not require long-term aspirin use after stent placement, Mount Sinai researchers report in a groundbreaking study

26 Sep 2019

ACC Asia Conference 2019 brings experts to discuss latest cardiovascular science

The American College of Cardiology and the Japanese College of Cardiology are hosting the 2019 ACC Asia Conference together with JCC 2019 in Nagoya, Japan, from September 13-14.

15 Sep 2019

Study indicates the benefits of stopping aspirin in heart attack patients

Patients who stopped taking aspirin three months after receiving a stent to open the heart's arteries but continued taking a P2Y12inhibitor—clopidogrel, prasugrel or ticagrelor—did not experience higher rates of death from any cause, heart attack or stroke after a year compared with those receiving standard therapy, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session.

19 Mar 2019

FDA approves new 5 mm diameter drug-eluting stent from Cook Medical

Cook Medical announced that a new 5 mm diameter version of Zilver® PTX® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths available up to 140 mm that is indicated to treat vessels as small as 4mm in diameter.

25 Sep 2018

Clinical study shows efficacy, safety of novel drug-eluting stent with improved radiographic visibility

This first randomized clinical study of a polymer-coated zotarolimus-eluting stent (Resolute Onyx) that utilizes a novel thin-strutted metallic platform allowing for better x-ray visibility was shown to be non-inferior to an ultrathin-strutted bioresorbable polymer-coated sirolimus-eluting stent (Orsiro) that uses a cobalt-chromium strut platform.

25 Sep 2018

Drug coated balloons are as good as stent implants for treating small blocked arteries

A removable balloon is as good as a permanent stent implant for opening small blocked arteries, according to late breaking results from the BASKET-SMALL 2 trial presented in a Hot Line Session today at ESC Congress 2018 and simultaneously published in The Lancet.

28 Aug 2018

Drug Eluting Stent News and Research

Further Reading

Intravascular imaging improves survival in heart disease patients undergoing stent placement

Extended P2Y12 inhibitor monotherapy reduces bleeding and ischemic events in ACS patients

OCT-guided PCI does not reduce target vessel failure in complex patients, but improves safety

Dual-antiplatelet therapy should remain the standard strategy for PCI even in the drug-eluting stent era

Bioresorbable vascular scaffolds may be just as effective as drug-eluting metal stents for treating heart disease patients

Research investigates how drug-eluting stent affects arterial tissue permeability and blood flow

New exosome-coated stent repairs damaged tissue, heals vascular injury

Study highlights the role of genetic testing in evaluation of in-stent thrombosis

Short, one-month dual anti-platelet treatment is safe and effective after stent placement

Study shows best antiplatelet treatment after transcatheter aortic valve implantation

TWILIGHT trial: Brilinta reduces bleeding compared to dual therapy in high-risk coronary patients

Polymer drug-eluting and polymer-free drug-coated stents safe and effective for patients with high bleeding risk

Ticagrelor monotherapy reduces bleeding while preserving ischemic benefit in high-risk PCI patients

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

High-risk heart patients may not require long-term aspirin use after stent placement

ACC Asia Conference 2019 brings experts to discuss latest cardiovascular science

Study indicates the benefits of stopping aspirin in heart attack patients

FDA approves new 5 mm diameter drug-eluting stent from Cook Medical

Clinical study shows efficacy, safety of novel drug-eluting stent with improved radiographic visibility

Drug coated balloons are as good as stent implants for treating small blocked arteries

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News